Table 4.

Overview of selected cetuximab q2w dosing studies in which KRAS mutational status was assessed

Patient characteristics	Patients, n		Dose and treatment	ORR, %	Median PFS, mo	Median OS, mo
	Total evaluable	KRAS-WT
KRAS WT prospectively selected
≥Third-line, irinotecan-, oxaliplatin-, and 5-FU-refractory mCRC63	30	30	Ctx 500 mg/m2 q2w + irinotecan	30	5.3	10.8
Second-line mCRC64	40	40	Ctx 500 mg/m2 q2w + irinotecan	45	7.1	18.5
KRAS WT retrospectively examined
First-line mCRC56	48	29	Ctx dose-escalation (400 to 700 mg/m2) q2w followed by Ctx + FOLFIRI	WT, 55 Mut, 32	WT, 9.4 Mut, 5.6	NR
Failed first-line fluoropyrimidine/ oxaliplatin regimens for mCRC61	31	8	Ctx 500 mg/m2 q2w + irinotecan	NR	WT, 2.6* Mut, 1.7*	WT, 14.1 Mut, 5.5

5-FU = 5-fluorouracil; Ctx = cetuximab; FOLFIRI = 5-fluorouracil + leucovorin + irinotecan; mCRC = metastatic colorectal cancer; Mut = KRAS mutant; NR = not reported; ORR = overall response rate; OS = overall survival; PFS = progression-free survival; q2w = every 2 weeks; WT = wild-type.

^*Reported as time to progression.